David Haffner - Glaukos Corp VP Technologies
| GKOS Stock | USD 112.72 2.02 1.82% |
Insider
David Haffner is VP Technologies of Glaukos Corp
| Address | One Glaukos Way, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0795) % which means that it has lost $0.0795 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2937) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.16 in 2024. At this time, Glaukos Corp's Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 640 M in 2024, whereas Total Assets are likely to drop slightly above 549.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Liu | Sight Sciences | N/A | |
| Marco Dolci | LivaNova PLC | 62 | |
| Stacey Desrochers | Bruker | N/A | |
| Jason Edie | Paragon 28 | N/A | |
| Barbara Schwarzentraub | CONMED | 53 | |
| Ehab Esmail | Orthofix Medical | 52 | |
| Julie Dewey | Nevro Corp | 63 | |
| Sam Park | Sight Sciences | 63 | |
| Michael Carter | Nevro Corp | 52 | |
| Matt Jarboe | Paragon 28 | N/A | |
| Jesse Selnick | Sight Sciences | N/A | |
| Donald Middlebrook | Nevro Corp | 69 | |
| Michelle Missal | Paragon 28 | N/A | |
| John Glenn | Iradimed Co | 62 | |
| Brendan Shook | Paragon 28 | N/A | |
| Steve Deitsch | Paragon 28 | N/A | |
| Meghan Scanlon | Paragon 28 | 48 | |
| McAlister Marshall | Integer Holdings Corp | 51 | |
| Karen Prange | Nevro Corp | 56 | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| Shanna Cottiosmanski | CONMED | 47 | |
Management Performance
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.0795 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mory Gharib, CoFounder | ||
| Gilbert Kliman, Independent Director | ||
| Michele Allegretto, Senior Resources | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Diane Biagianti, Sr Counsel | ||
| David Hoffmeister, Independent Director | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Denice Torres, Independent Director | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Tomas Navratil, Chief Development Officer | ||
| Jane Rady, Senior Development | ||
| Aimee Weisner, Independent Director | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.0795 | ||||
| Profit Margin | (0.43) % | ||||
| Operating Margin | (0.32) % | ||||
| Current Valuation | 5.79 B | ||||
| Shares Outstanding | 50.37 M | ||||
| Shares Owned By Insiders | 3.48 % | ||||
| Shares Owned By Institutions | 96.52 % | ||||
| Number Of Shares Shorted | 3.25 M | ||||
| Price To Earning | 94.70 X |
Pair Trading with Glaukos Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Glaukos Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Glaukos Corp will appreciate offsetting losses from the drop in the long position's value.Moving together with Glaukos Stock
| 0.68 | ESTA | Establishment Labs | PairCorr |
Moving against Glaukos Stock
| 0.93 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
| 0.92 | VMD | Viemed Healthcare | PairCorr |
| 0.91 | CVS | CVS Health Corp Buyout Trend | PairCorr |
| 0.91 | SSY | SunLink Health Systems | PairCorr |
| 0.89 | XTNT | Xtant Medical Holdings | PairCorr |
The ability to find closely correlated positions to Glaukos Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Glaukos Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Glaukos Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Glaukos Corp to buy it.
The correlation of Glaukos Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Glaukos Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Glaukos Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Glaukos Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Glaukos Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Glaukos Stock please use our How to Invest in Glaukos Corp guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Glaukos Stock analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Glaukos Corp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Glaukos Corp. If investors know Glaukos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Glaukos Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 18.963 | Earnings Share (2.89) | Revenue Per Share 6.681 | Quarterly Revenue Growth 0.159 | Return On Assets (0.08) |
The market value of Glaukos Corp is measured differently than its book value, which is the value of Glaukos that is recorded on the company's balance sheet. Investors also form their own opinion of Glaukos Corp's value that differs from its market value or its book value, called intrinsic value, which is Glaukos Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Glaukos Corp's market value can be influenced by many factors that don't directly affect Glaukos Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Glaukos Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Glaukos Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Glaukos Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.